apatinib in combination with docetaxel for patients with advanced nsclc

Conditions: Lung Cancer

Summary: in order to explore a new treatment strategy for patients with failed nsclc platinum-containing double-drug therapy, this study was to investigate the clinical efficacy of apatinib in combination with docetaxel for patients with advanced nsclc after failure of platinum-based regime


Eligibility criteria:
inclusion criteria: 1. ecog 0-2; 2. expected survival of not less than 12 weeks; 3. the first line of platinum-containing chemotherapy, pathologically confirmed iiib, iv non-small cell lung cancer, with measurable lesions (according to the recist 1.1 standard, ct lesion tumor diameter ≥ 10mm, lymph node lesion ct scan diameter ≥ 15mm, measurable lesions have not received radiotherapy, local treatment such as freezing) 4. the main organs function properly 5. women of childbearing age must have had reliable contraception or have had a pregnancy test (serum or urine) within 7 days prior to enrollment with a negative result and are willing to take appropriate measures 8 weeks after and during the last administration of the test drug contraception. in the case of males, consent is to be given to contraception or surgical sterilization 8 weeks after and during the last administration of the test drug; 6. participants volunteered to join the study and signed informed consent form, with good compliance and follow-up. exclusion criteria: 1. imaging (ct or mri) showed tumor lesions away from the large blood vessels ≤ 5mm, or the presence of invasive central local blood vessels of the central tumor; or showed the presence of significant lung empty or necrotic tumors; 2. uncontrolled hypertension (systolic bp ≥140 mmhg or diastolic bp ≥90 mmhg, despite optimal drug therapy); 3. has the following cardiovascular disease: myocardial ischemia or myocardial infarction with grade ii or higher, poorly controlled arrhythmia (including qtc intercourse men ≥ 450ms, women ≥ 470ms); nyha class iii-iv cardiomyopathy, or cardiac ultrasound examination prompted left ventricular ejection fraction (lvef) \<50%; 4. hemoptysis (inr\> 1.5 or prothrombin time (pt)\> uln + 4 seconds or aptt\> 1.5uln) with bleeding tendency or undergoing thrombolytic or anticoagulant therapy; 5. in the first 2 months before enrollment, there is obvious slightly blood, or daily hemoptysis volume of 2.5ml or more; 6. within 3 months prior to enrollment, significant clinically significant bleeding symptoms or definite bleeding tendencies such as gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ at baseline, and above, or vasculitis; 7. incidence of arterial / venous thrombosis within the first 12 months of enrollment such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; 8. known hereditary or acquired bleeding and thrombophilia (eg hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc); 9. factors that significantly affect the absorption of oral drugs, such as non-swallowing, chronic diarrhea and intestinal obstruction; 10. urine routine urinary protein ≥ ++, or confirmed 24-hour urinary protein content ≥ 2.0g; 11. previous or concurrent with other unhealed malignancies, except for those having had a cure for cutaneous basal cell carcinoma, carcinoma of the cervix, and superficial bladder cancer; 12. pregnant or lactating women; reproductive patients who are unwilling or unable to take effective contraception; 13. the investigators determine other situations that may affect clinical research and outcome decisions.